Vitiligo - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Vitiligo Emerging Therapy and TPP Insights

Thelansis's "Vitiligo Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Vitiligo Overview

Vitiligo is a chronic autoimmune skin disorder in which immune-mediated destruction and dysfunction of melanocytes cause well-demarcated areas of depigmentation. The condition can affect any skin site and may involve the hair, mucosal surfaces, and other pigment-bearing tissues. Its course is variable, ranging from stable localized disease to periods of active spread, and spontaneous repigmentation can occur in some patients. Beyond its visible manifestations, vitiligo can substantially affect quality of life, contributing to psychosocial distress, stigma, and reduced confidence. Treatment aims to control disease activity and restore pigmentation through topical corticosteroids, topical calcineurin inhibitors, phototherapy, and, in selected patients, surgical approaches. However, responses can be incomplete, relapse is common, and achieving durable repigmentation remains challenging, particularly in longstanding or extensive disease. These limitations have accelerated development of targeted immunomodulatory therapies, including JAK inhibitors and other pathway-directed approaches, alongside strategies designed to enhance melanocyte recovery and repigmentation.

Key Highlights

• In Spain, the prevalent Vitiligo population is projected to increase from 197,576 in 2026 to 206,690 by 2036.
• Vitiligo is a chronic autoimmune skin disorder characterized by loss of skin pigmentation.
• Visible skin changes can significantly affect patients' quality of life and psychosocial well-being.
• Significant unmet need remains for effective and durable repigmentation therapies.

Market Overview

• The France Vitiligo market is projected to grow from $110M in 2026 to $275M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies, including topical and systemic treatments
• Growing disease awareness and diagnosis
• Future growth will depend on therapies providing durable repigmentation and sustained disease control.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Minghui Pharmaceutical (Hangzhou) Ltd
• Pfizer
• AbbVie
• Jiangsu HengRui Medicine Co., Ltd.
• Genrix (Shanghai) Biopharmaceutical Co., Ltd.
• Incyte Corporation
• Forte Biosciences, Inc.
• CAGE Bio Inc.
• Clinuvel, Inc.
• InventisBio Co., Ltd.
• Eli Lilly and Company